DUBLIN--(BUSINESS WIRE)--The "Degenerative Disc Disease - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Degenerative Disc Disease - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 4 and 3 respectively.
Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Report Coverage
- Degenerative Disc Disease - Overview
- Degenerative Disc Disease - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Degenerative Disc Disease - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Degenerative Disc Disease - Companies Involved in Therapeutics Development
- AnGes Inc
- Biopharm GmbH
- BioRestorative Therapies Inc
- Bone Therapeutics SA
- DiscGenics Inc
- Kolon TissueGene Inc
- Osiris Therapeutics Inc
- Samumed LLC
- U.S. Stem Cell Inc
- Yuhan Corp
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/f9p834/degenerative_disc?w=4
